A novel indirect holographic technique for the early detection of breast cancer, which offers considerable benefits in terms of simplicity and expense, is presented and discussed. It is shown how this approach, usually employed at optical frequencies, can be adapted to image breast tumors at microwa
Characterization of benign and malignant breast tissues using 2-D microwave tomographic imaging
✍ Scribed by G. Bindu; K. T. Mathew
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 301 KB
- Volume
- 49
- Category
- Article
- ISSN
- 0895-2477
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Dielectric permittivity studies and 2‐D microwave tomographic imaging are performed on benign and malignant breast tissues to characterize these tumors at the ISM band. Significant difference in the permittivity values is obtained and a distinct characterization is done based on the nature of the permittivity profiles. Also, it is observed that benign tumors exhibit sharp images with well‐defined borders, whereas malignant tumors show fuzzy and blurred boundaries. © 2007 Wiley Periodicals, Inc. Microwave Opt Technol Lett 49: 2341–2345, 2007; Published online in Wiley InterScience (www.interscience.wiley.com) DOI 10.1002/mop.22734
📜 SIMILAR VOLUMES
## Abstract ## Purpose To determine whether combining 3D fast imaging employing steady‐state acquisition (FIESTA) and T1‐weighted contrast‐enhanced (CE) sequences could help characterize lesions in 32 women with benign, in situ, or invasive breast lesions. Since FIESTA provides both T1 and T2 info
## Abstract ## Purpose To determine the association between morphological changes to the deep fascia and the malignancy of soft‐tissue tumors in the lower limbs using 3.0 T magnetic resonance imaging (MRI). ## Materials and Methods MR images of 47 consecutive patients with 48 pathologically prov
## Abstract ## BACKGROUND. This study was designed to investigate the fluorine‐18 fluorodeoxyglucose (FDG)‐positron emission tomography (PET) imaging characteristics of triple‐negative (estrogen receptor‐negative [ER−]/progesterone receptor‐negative [PR−]/HER2‐negative [HER2−]) breast carcinoma an